UroGen Pharma (NASDAQ:URGN – Free Report) had its price target lifted by HC Wainwright from $23.00 to $54.00 in a report published on Tuesday, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q3 2023 earnings at ($0.86) EPS, Q4 2023 earnings at ($0.54) […]
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target increased by HC Wainwright from $23.00 to $54.00 in a research note released on Tuesday, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for UroGen Pharma’s Q3 2023 earnings at ($0.86) EPS, Q4 2023 earnings at […]
UroGen Pharma (NASDAQ:URGN – Free Report) had its target price raised by Oppenheimer from $22.00 to $33.00 in a research report released on Friday, FlyOnTheWall reports. UroGen Pharma Trading Down 4.2 % Shares of NASDAQ:URGN opened at $21.66 on Friday. The stock has a market capitalization of $492.55 million, a PE ratio of -4.48 and […]
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) hit a new 52-week high during trading on Friday after Oppenheimer raised their price target on the stock from $22.00 to $33.00. The stock traded as high as $23.38 and last traded at $22.68, with a volume of 4657877 shares trading hands. The stock had […]